Last reviewed · How we verify
MITT
MITT is a mitochondrial-targeted therapeutic that enhances mitochondrial function and cellular energy production.
At a glance
| Generic name | MITT |
|---|---|
| Also known as | Open triple therapy combination |
| Sponsor | AstraZeneca |
| Target | Mitochondrial electron transport chain |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
MITT works by improving mitochondrial oxidative phosphorylation and ATP synthesis, thereby restoring cellular energy metabolism. This mechanism is intended to address diseases characterized by mitochondrial dysfunction or cellular energy deficiency. The drug targets the mitochondrial electron transport chain to enhance aerobic respiration.
Approved indications
Common side effects
Key clinical trials
- Constraint-Induced Movement Therapy for Adults Post-Stroke With Mild Upper Extremity Impairment (NA)
- Constraint Induced Movement Therapy and Bilateral Training in Chronic Stroke (NA)
- Constraint-induced Movement Therapy Versus Task-oriented Training On Upper Extremity Function Post-Botox Injection in Stroke Patients (NA)
- Effects of tVNS and mCIMT in Chronic Stroke (NA)
- Effects of Modified CIMT With and Without PNF (NA)
- Changes in Movement, Fitness, and Quality of Life in People With Parkinson's Disease After Different Exercise Programs (NA)
- Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy (NA)
- A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |